BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of BAVARIAN NORDIC/S (OTCMKTS:BVNRY) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Shares of OTCMKTS:BVNRY opened at $8.27 on Wednesday. The company has a market cap of $801.61 million, a PE ratio of -14.02 and a beta of 0.59. BAVARIAN NORDIC/S has a 1-year low of $5.92 and a 1-year high of $10.42. The company has a debt-to-equity ratio of 0.22, a current ratio of 9.34 and a quick ratio of 9.01. The stock’s 50-day moving average price is $7.72.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last announced its quarterly earnings results on Wednesday, May 22nd. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $19.29 million during the quarter, compared to the consensus estimate of $21.15 million. BAVARIAN NORDIC/S had a negative net margin of 45.38% and a negative return on equity of 12.56%. Sell-side analysts expect that BAVARIAN NORDIC/S will post -0.56 EPS for the current fiscal year.

About BAVARIAN NORDIC/S

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Featured Article: What is the float in trading stocks?

Get a free copy of the Zacks research report on BAVARIAN NORDIC/S (BVNRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.